Clinical Effect of Low Dose Tetraiodothyronine in Hepatic Fibrosis Activity on Compensated Cirrhosis with T3 Degraded
10.3760/cma.j.issn.1008-6706.2009.11.038
- VernacularTitle:小剂量甲状腺素对低T_3代偿期肝硬化的影响
- Author:
Jie CHEN
- Publication Type:Journal Article
- Keywords:
Tetraiodothyronine;
Hepatic fibrosis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2009;16(11):1990-1991
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To investigate change of Tetraiodothyronine(TH)in serum on compensated cirrhosis with T_3 degraded and observe the effect of TH in hepatic fibrosis activity.Methods Sixty patients were randomly divided into experimental group and control group.The patients in experimental group and control group received same treatment,including protecting hepatic function and nutritional support.TH were taken to experimental group with 25 mg/d for a month.clinical effect were estimated,Hepatic function and hepatic fibrosis activity were measured in serum on all patients when the treatment was over.Results In comparison with control group,the levels of AST、ALT、HA、LN、PC-Ⅲand C-Ⅳin serum were lower,the level of ALB Was indiscriminate,and proportionality of A/G was higher in cirrhosis.Clinical effect was same in two groups.Conclusion The level of TH in serum was decreasing in compensation cirrhosis,and additional TH can decrease hepatic fibrosis activity,but can not improve clinical effect in short.
